Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy

By sjmartinez • June 3, 2024

Miller JE, Taylor-Cousar JL, Overdevest JB, Khatiwada A, Mace JC, Alt JA, Bodner TE, Chowdhury NI, DiMango EA, Eshaghian PH, Getz AE, Gudis DA, Han EJ, Hwang PH, Keating CL, Khanwalkar A, Kimple AJ, Lee JT, Li D, Markarian K, Norris M, Nayak JV, Owens C, Patel ZM, Poch K, Schlosser RJ, Smith KA, Smith TL, Soler ZM, Suh JD, Tervo JP, Turner GA, Wang MB, Saavedra MT, Beswick DM. Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy. Int Forum Allergy Rhinol. 2024 Jun;14(6):1079-1087. doi: 10.1002/alr.23312. Epub 2023 Dec 25. PMID: 38145393.

Tags: chronic rhinosinusitis, cystic fibrosis, highly effective modulator therapy, olfaction, olfactory disorders, olfactory dysfunction, olfactory test, patient‐reported outcome measure, Publications, Pulmonary, Critical Care & Sleep Medicine, Quality of Life

Related Posts

Genetic profiling of synchronous pituitary corticotroph adenomas

Zhang D, Tsai K, Santana C, Javaherian K, Lee M, Bergsneider M, Kim W, Wang MB, Vinters HV, Yan W, Heaney AP. Genetic profiling of[...]

Uptake of the COVID-19 vaccine and its association with vaccine information and misinformation in Malawi

Songo J, Whitehead HS, Phiri K, Kalande P, Lungu E, Phiri S, van Oosterhout J, Moses A, Hoffman RM, Moucheraud C. Uptake of the COVID-19[...]

Implementing a Cardiology Quality Incentive Program to Improve Guideline-Directed Medical Therapy

Cho DJ, Bokhoor PI, Dermenchyan A, Brownell N, Delavin NL, Furlong S, Hoo J, Tibbe T, Chen LY, Vangala S, Waterman BA, Han M, Fonarow[...]